ISTERIAN
Live / Registered — Registered (as of 25 Mar 2025)
What this means for you
Registered since 25 Mar 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97705569
- Registration number
- 7739812
- Mark type
- Stylized text
- Filed
- 06 Dec 2022
- Published for opposition
- 07 May 2024
- Registered
- 25 Mar 2025
- Attorney of record
- Matthew D. Delaney
Goods and services
- Class 042 — Scientific and technological services: Drug discovery services; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical products development; Pharmaceutical research and development; Research and development in the field of inhibiting and reducing the pathological accumulation of extracellular matrix proteins; Research and development in the field of fibrosis; Scientific research for medical purposes in the field of fibrosis; Scientific research for medical purposes in the field of inhibiting and reducing the pathological accumulation of extracellular matrix proteins
Owner
- Cambrian BioPharma, Inc., New York, NY, US
- Cambrian BioPharma, Inc., New York, NY, US
- Cambrian BioPharma, Inc., New York, NY, US
Prosecution history
- 25 Mar 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 25 Mar 2025 — REGISTERED-PRINCIPAL REGISTER
- 05 Mar 2025 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 05 Mar 2025 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 21 Feb 2025 — STATEMENT OF USE PROCESSING COMPLETE
- 09 Dec 2024 — USE AMENDMENT FILED
- 20 Feb 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 09 Dec 2024 — TEAS STATEMENT OF USE RECEIVED
- 02 Jul 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 07 May 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 07 May 2024 — PUBLISHED FOR OPPOSITION
- 17 Apr 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 01 Apr 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 27 Feb 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 27 Feb 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE